Christopher Cline Net Worth & Insider Trades
Christopher Cline - Chief Financial Officer, Travere Therapeutics, Inc
What is Christopher Cline's Net Worth?
The current estimated net worth of Travere Therapeutics, Inc's Chief Financial Officer, Christopher Cline, is estimated to be about $768.47K . Christopher Cline owns about 51,533 units of Travere Therapeutics, Inc common stock. In the last year at Travere Therapeutics, Inc, Christopher Cline has sold an estimated value of $53.2K worth.
What is Christopher Cline's Past Insider Trading?
Christopher Cline's largest sale order was 1,588 units , worth over $34.54K on February 2, 2023. In total, Christopher Cline has made about 3 transactions over a year of their time at Travere Therapeutics, Inc. Christopher Cline usually trades in September, February and January, with the busiest year in 2023.
Christopher Cline
Date Range: All Time
Ticker
|
Type
|
Value
|
Price per Share
|
Shares
|
Filing Date
| ||
|---|---|---|---|---|---|---|---|
| No matching records found | |||||||
What is Christopher Cline's' Mailing Address?
- Mailing address is C/o Travere Therapeutics, Inc. 3611 Valley Centre Drive, Ste 300 San Diego CA 92130 CA
Travere Therapeutics, Inc Executive Compensation
Name |
Year
|
Salary
|
Bonus
|
Other Earnings Plans or Compensations
|
Stock Awards
|
Option Awards
|
Other Compensation
|
Total
|
|---|---|---|---|---|---|---|---|---|
| Eric Dube, Ph.D. | 2020 | $660,938 | - | $457,125 | $1,546,000 | $2,772,090 | $11,726 | $5,447,879 |
| Eric Dube, Ph.D. | 2019 | $618,188 | $100,000 | $337,500 | $2,441,760 | $5,977,280 | $204,591 | $9,679,319 |
| Laura Clague | 2020 | $436,801 | - | $254,239 | $432,880 | $508,217 | $16,577 | $1,648,714 |
| Laura Clague | 2019 | $419,271 | - | $200,747 | $215,520 | $453,000 | $15,044 | $1,303,582 |
| Laura Clague | 2018 | $399,583 | - | $185,150 | $497,803 | $769,522 | $8,250 | $1,860,308 |
| Elizabeth Reed | 2020 | $413,417 | - | $235,463 | $432,880 | $508,217 | $11,214 | $1,601,191 |
| Elizabeth Reed | 2019 | $391,667 | - | $187,500 | $215,520 | $453,000 | $10,760 | $1,258,447 |
| Elizabeth Reed | 2018 | $347,500 | - | $161,000 | $391,180 | $673,331 | $8,250 | $1,581,261 |
| Noah Rosenberg, M.D. | 2020 | $447,002 | - | $254,573 | $432,880 | $508,217 | $12,360 | $1,655,032 |
| Noah Rosenberg, M.D. | 2019 | $432,083 | - | $195,075 | $215,520 | $453,000 | $73,965 | $1,369,643 |
| Noah Rosenberg, M.D. | 2018 | $183,622 | $100,000 | $97,750 | $571,600 | $1,183,611 | $266,500 | $2,403,083 |
| William E. Rote, Ph.D. | 2020 | $447,474 | - | $254,800 | $432,880 | $508,217 | $14,303 | $1,657,674 |
| William E. Rote, Ph.D. | 2019 | $432,858 | - | $195,736 | $215,520 | $453,000 | $13,112 | $1,310,226 |
| William E. Rote, Ph.D. | 2018 | $420,250 | - | $194,258 | $370,531 | $625,236 | $8,250 | $1,618,525 |
| No matching records found | ||||||||
Source: https://www.sec.gov/Archives/edgar/data/1438533/000143853321000012/tvtx-2021definitiveproxy.htm
What are Travere Therapeutics, Inc's Past Insider Trades?
Travere Therapeutics, Inc's most recent insider trade came on February 2, 2023 by Elizabeth E Reed who sold 2,590 units worth $57.63K . In the last 3 years, insiders at Travere Therapeutics, Inc have sold an estimated value of $10.82M and bought an estimated value of $1.71M worth of shares. Insider trading is most common in February, with the busiest year in 2021. The most active traders at the company are Eric Dube, Chief Executive Officer, Elizabeth E Reed, SVP, and William Rote, Senior Vice President .
Travere Therapeutics, Inc. Insider Trades
Date Range: All Time
Insider Names
|
Type
|
Value
|
Price per Share
|
Shares
|
Filing Date
| ||
|---|---|---|---|---|---|---|---|
| No matching records found | |||||||